These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37234387)

  • 1. Predictors of in-hospital mortality in elderly patients with heart failure treated with tolvaptan.
    Kobayashi M; Hayashi M; Yamada R; Ishiguro T; Fujiwara W; Ishii H; Naruse H; Watanabe E; Ozaki Y; Izawa H
    Fujita Med J; 2023 May; 9(2):80-83. PubMed ID: 37234387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the early use of V2 receptor antagonists in elderly patients with decompensated heart failure.
    Matsukawa R; Kubota T; Okabe M; Yamamoto Y; Meno H
    Heart Vessels; 2018 Feb; 33(2):145-154. PubMed ID: 28815407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Initiation and long-term use of tolvaptan for patients with worsening heart failure through hospital and clinic cooperation.
    Uemura Y; Shibata R; Ishikawa S; Takemoto K; Murohara T; Watarai M
    Nagoya J Med Sci; 2021 Aug; 83(3):431-441. PubMed ID: 34552281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Good response to tolvaptan shortens hospitalization in patients with congestive heart failure.
    Kogure T; Jujo K; Hamada K; Saito K; Hagiwara N
    Heart Vessels; 2018 Apr; 33(4):374-383. PubMed ID: 29128962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood urea nitrogen to serum albumin ratio: a good predictor of in-hospital and 90-day all-cause mortality in patients with acute exacerbations of chronic obstructive pulmonary disease.
    Zeng Z; Ke X; Gong S; Huang X; Liu Q; Huang X; Cheng J; Li Y; Wei L
    BMC Pulm Med; 2022 Dec; 22(1):476. PubMed ID: 36522751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood Urea Nitrogen/Creatinine Ratio and Response to Tolvaptan in Patients with Decompensated Heart Failure: A Retrospective Analysis.
    Okayama D; Suzuki T; Shiga T; Minami Y; Tsuruoka S; Hagiwara N
    Am J Cardiovasc Drugs; 2015 Aug; 15(4):289-93. PubMed ID: 25940650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment.
    Vaduganathan M; Gheorghiade M; Pang PS; Konstam MA; Zannad F; Swedberg K; Grinfeld L; Burnett JC; Krasa HB; Zimmer C; Blair J; Ouyang J; Maggioni AP;
    J Cardiovasc Med (Hagerstown); 2012 Jul; 13(7):415-22. PubMed ID: 22673023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood urea nitrogen/creatinine ratio identifies a high-risk but potentially reversible form of renal dysfunction in patients with decompensated heart failure.
    Brisco MA; Coca SG; Chen J; Owens AT; McCauley BD; Kimmel SE; Testani JM
    Circ Heart Fail; 2013 Mar; 6(2):233-9. PubMed ID: 23325460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors for long-term outcomes in acute decompensated heart failure patients under tolvaptan treatment.
    Matsumura K; Morishita S; Taniguchi N; Takehana K; Takahashi H; Otagaki M; Yoshioka K; Yamamoto Y; Takagi M; Shiojima I
    Heart Vessels; 2019 Apr; 34(4):607-615. PubMed ID: 30386917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure.
    Matsukawa R; Kubota T; Okabe M; Yamamoto Y
    Heart Vessels; 2016 Oct; 31(10):1650-8. PubMed ID: 26676672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Impact of the Early Use of Tolvaptan in Elderly Patients with Acute Decompensated Heart Failure.
    Okada T; Miyoshi T; Oka A; Tsushima R; Sudo Y; Seiyama K; Takagi W; Kawaguchi T; Ozaki M; Sogo M; Ugawa S; Nosaka K; Takahashi M; Okawa K; Doi M
    J Clin Med; 2023 Apr; 12(9):. PubMed ID: 37176546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction.
    Matsue Y; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; Goldsmith SR
    Int J Cardiol; 2016 Oct; 221():188-93. PubMed ID: 27404673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The characteristics and outcomes in patients with acute heart failure who used tolvaptan: from KCHF registry.
    Nishikawa R; Kato T; Morimoto T; Yaku H; Inuzuka Y; Tamaki Y; Yamamoto E; Ozasa N; Tada T; Sakamoto H; Seko Y; Shiba M; Yoshikawa Y; Yamashita Y; Kitai T; Taniguchi R; Iguchi M; Nagao K; Kawai T; Komasa A; Kawase Y; Morinaga T; Toyofuku M; Furukawa Y; Ando K; Kadota K; Sato Y; Kuwahara K; Kimura T;
    ESC Heart Fail; 2023 Oct; 10(5):3141-3151. PubMed ID: 37644779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.
    Lanfear DE; Sabbah HN; Goldsmith SR; Greene SJ; Ambrosy AP; Fought AJ; Kwasny MJ; Swedberg K; Yancy CW; Konstam MA; Maggioni AP; Zannad F; Gheorghiade M;
    Circ Heart Fail; 2013 Jan; 6(1):47-52. PubMed ID: 23239836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renoprotective effect of tolvaptan in patients with new-onset acute heart failure.
    Kin H; Matsumura K; Yamamoto Y; Fujii K; Otagaki M; Takahashi H; Park H; Yoshioka K; Yokoi M; Sugiura T; Shiojima I
    ESC Heart Fail; 2020 Aug; 7(4):1764-1770. PubMed ID: 32383323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of renal predictors for in-hospital and postdischarge mortality after hospitalized heart failure.
    Singh G; Peterson EL; Wells K; Williams LK; Lanfear DE
    J Cardiovasc Med (Hagerstown); 2012 Apr; 13(4):246-53. PubMed ID: 22343264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early initiation of tolvaptan is associated with early discharge in patients with heart failure regardless of age.
    Kiuchi S; Hisatake S; Kabuki T; Oka T; Dobashi S; Murakami Y; Sano T; Ikeda T
    BMC Cardiovasc Disord; 2022 Apr; 22(1):202. PubMed ID: 35488212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood urea nitrogen variation upon admission and at discharge in patients with heart failure.
    Khoury J; Bahouth F; Stabholz Y; Elias A; Mashiach T; Aronson D; Azzam ZS
    ESC Heart Fail; 2019 Aug; 6(4):809-816. PubMed ID: 31199082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial).
    Vaduganathan M; Greene SJ; Ambrosy AP; Mentz RJ; Subacius HP; Chioncel O; Maggioni AP; Swedberg K; Zannad F; Konstam MA; Senni M; Givertz MM; Butler J; Gheorghiade M;
    Am J Cardiol; 2014 Dec; 114(11):1713-21. PubMed ID: 25312638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.